No Winner In Nanjing Medical And Xian-Janssen Breakup
This article was originally published in PharmAsia News
After breaking up their collaboration in 2007, Nanjing Medical and Xian-Janssen have made no progress in resuming their business negotiation. Xian-Janssen, the biggest OTC producer in China, has found another channel partner in Nanjing; Nanjing Medical on its part has taken up distributorship of alternative products. The standoff has not benefited either party. Xian-Janssen's key drug Motilium sees lower sales, while Nanjing Medical's newly released 2007 annual report shows that its pharmaceutical distribution profit growth only increased 0.21 percentage points compared to the previous year. Industry observers note that to achieve a win-win situation, pharmaceutical producers should give reasonable profit margins to distributors, which in turn should value the manufacturers' brand names. (Click here for more - Chinese Language)
You may also be interested in...
Nanjing Medical and Xian-Janssen have ended their dispute over drug distribution (PharmAsia News, March 31, 2008), according to an insider, but the detailed compromise solution is not disclosed. The strained relations between the two firms have impacted Xian-Janssen's revenue, which dropped 20 to 30 percent in 2008. Based on the previous model, Nanjing Medical is now directly distributing Xian-Janssen's drugs in Fujian and Anhui provinces. However, Jiangsu is covered by Nanjing Huadong Medicine, which is Nanjing Medical's sister subsidiary under Nanjing Medical Industry (Group). The move shows Xian-Janssen's willingness to work indirectly with Nanjing Medical to avoid losing the latter's Jiangsu clients comprising 167 hospital pharmacies. (Click here for more - Chinese Language)
The merger between virtual care companies Teladoc and Livongo will offer individuals a wide range of tech-enabled care during a time when telehealth continues to grow.
Regeneron's antibody cocktail for SARS-Cov-2 is largely in holding mode for now, but the company announced progress on other fronts including for Dupixent in COPD and the NGF inhibitor fasinumab.